BioNTech SE Sponsored ADR (NASDAQ:BNTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) have been assigned an average recommendation of “Moderate Buy” from the eighteen research firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, twelve have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $133.1333.

BNTX has been the subject of a number of recent research reports. Raymond James Financial reiterated an “outperform” rating on shares of BioNTech in a research report on Tuesday, March 10th. Bank of America restated a “buy” rating and issued a $128.00 target price on shares of BioNTech in a report on Tuesday, March 10th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of BioNTech in a research report on Tuesday, March 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research report on Friday, January 23rd.

BioNTech Stock Performance

Shares of BNTX opened at $95.50 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.49. The firm’s 50 day moving average is $98.81 and its 200-day moving average is $101.02. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The stock has a market capitalization of $24.00 billion, a P/E ratio of -18.23 and a beta of 1.58.

BioNTech (NASDAQ:BNTX) last released its earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The business had revenue of $1.06 billion for the quarter. BioNTech had a negative net margin of 38.09% and a negative return on equity of 4.76%. Equities research analysts anticipate that BioNTech will post -3.88 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dodge & Cox lifted its position in shares of BioNTech by 315.7% in the 3rd quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares in the last quarter. GSK plc purchased a new stake in shares of BioNTech in the 4th quarter valued at approximately $84,711,000. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 43.0% in the 4th quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock valued at $150,235,000 after acquiring an additional 474,796 shares in the last quarter. Bank of America Corp DE raised its position in BioNTech by 344.4% during the third quarter. Bank of America Corp DE now owns 573,356 shares of the company’s stock valued at $56,544,000 after buying an additional 444,332 shares during the period. Finally, Voloridge Investment Management LLC acquired a new position in BioNTech during the fourth quarter valued at $41,656,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.